Renal Cell Carcinoma

The treatment of kidney cancer has been re-energised by the introduction of novel therapeutics and innovative surgical advances. Edited and written by medical oncologists and surgeons, this new reference covers the full spectrum of renal cell carcinoma from screening, epidemiology, and pathology to molecular genetics, surgical management, and therapy of metastatic disease. Front and centre is the biology of renal cell carcinoma, where researchers have made great progress in expanding our understanding of mechanisms and processes making therapeutic advances possible. This atlas includes the latest information on the immunobiology of kidney cancer as well as pathways involving vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR). The bulk of the chapters deal with the practical management of the continuum of kidney cancer ranging from the small renal mass, through locally advanced disease, to the metastatic patient. Different treatment approaches are discussed within the context of each of these clinical scenarios, and surgical and therapeutic advances are highlighted. In addition, special populations such as patients requiring palliative care, those with brain or bone metastasis, and those with inherited renal cell carcinoma are discussed. Key Features Up to date discussion of the newest data on targeted agents Comprehensive analysis of all aspects of RCC management Chapters of special clinical interests including Partial Nephrectomy, Angiogenesis Biology, and Rapamycin Inhibition Extensive details on new research pathways in VEGF and mTOR Extensive description of imaging techniques